VANCOUVER, BC , Dec. 4, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US... Read More

VANCOUVER, BC , Sept. 18, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this... Read More

VANCOUVER, BC , Sept. 12, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology. The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of... Read More

VANCOUVER, BC , July 24, 2023 /CNW/ - PreveCeutica l Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information. PreveCeutical plans to use this... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A forum on April 25, 2023. All participants are encouraged to pre-register to ensure access to the live virtual event and to submit any questions... Read More

Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria, KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844H PreveCeutical's Pain Management Peptides Program Published in the Swiss Medical Journal. Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023 , to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective February 17, 2023. Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ( "Endosane") , a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of... Read More